evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,138 questions · 1,154 findings · 139 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 184 · 15.9%GRADE not reported 183 · 15.9%Very low 273 · 23.7%Low 296 · 25.6%Moderate 171 · 14.8%High 47 · 4.1%

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)

Clinical response: no clinically significant response in mental state: 20% to 50% reduction in PANSS total score · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).

1 finding from 1 review

CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001)

Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)

Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).

1 finding from 1 review